<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="2.3" xml:lang="EN">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher-id">DIJ</journal-id>
         <journal-id journal-id-type="hwp">spdij</journal-id>
         <journal-title>Drug Information Journal</journal-title>
         <issn pub-type="ppub">0092-8615</issn>
         <publisher>
            <publisher-name>SAGE Publications</publisher-name>
            <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.1177/0092861512457774</article-id>
         <article-id pub-id-type="publisher-id">10.1177_0092861512457774</article-id>
         <article-categories>
            <subj-group subj-group-type="heading">
               <subject>Commentary</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>Editor’s Commentary: A New Category of Articles— Regulatory Commentaries</article-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Turner</surname>
                  <given-names>J. Rick</given-names>
               </name>
               <degrees>PhD</degrees>
               <xref ref-type="aff" rid="aff1-0092861512457774"/>
            </contrib>
            <aff id="aff1-0092861512457774">
               <italic>Editor-in-Chief</italic>
            </aff>
         </contrib-group>
         <pub-date pub-type="epub-ppub">
            <month>9</month>
            <year>2012</year>
         </pub-date>
         <volume>46</volume>
         <issue>5</issue>
         <fpage>517</fpage>
         <lpage>518</lpage>
         <permissions>
            <copyright-statement>© The Author(s) 2012</copyright-statement>
            <copyright-year>2012</copyright-year>
            <copyright-holder content-type="society">Drug Information Association</copyright-holder>
         </permissions>
      </article-meta>
   </front>
   <body>
      <p>As noted in my commentary in the last issue of the journal,<sup>
            <xref ref-type="bibr" rid="bibr1-0092861512457774">1</xref>
         </sup> we are truly excited as we approach the renaming of the journal with the January 2013 issue to become <italic>Therapeutic Innovation &amp; Regulatory Science. </italic>The theme of the 2013 DIA North America Annual Meeting, “Advancing Therapeutic Innovation &amp; Regulatory Science,” bears witness to the importance of the journal to DIA itself.</p>
      <p>At the very successful 2012 Annual Meeting, held in Philadelphia at the end of June, there were many sessions relevant to these topics. One in particular that is noteworthy in the context of our expanding interest in regulatory science was titled “Regulatory Collaboration/21st Century Innovation: Views of the Heads of Health Canada, the European Medicines Agency, and the US FDA.” It brought together Mr Paul Glover, Professor Guido Rasi, and Dr Margaret Hamburg, respectively, to share their views on various topics pertaining to regulation of medical products in various jurisdictions. Topics included:</p>
      <list list-type="bullet">
         <list-item>
            <p>How do agencies meet their domestically focused mission in an increasingly global environment? </p>
         </list-item>
         <list-item>
            <p>What will regulatory collaboration look like as we go further into the 21st century? </p>
         </list-item>
         <list-item>
            <p>How do you integrate local community perspectives and needs into initiatives to increase collaborative interactions with other agencies to innovate public health worldwide? </p>
         </list-item>
         <list-item>
            <p>How does an agency share international values with its primarily local constituents, especially parliamentary overseers?</p>
         </list-item>
      </list>
      <p>Additionally, in response to a question from the audience, Dr Hamburg shared her latest thinking on the term <italic>regulatory science</italic>, a term she has used for several years<sup>
            <xref ref-type="bibr" rid="bibr2-0092861512457774">2</xref>
         </sup> and that appears prominently in recent FDA documents.<sup>
            <xref ref-type="bibr" rid="bibr3-0092861512457774">3</xref>,<xref ref-type="bibr" rid="bibr4-0092861512457774">4</xref>
         </sup> Similar interest in regulatory science is evident at the European Medicines Agency<sup>
            <xref ref-type="bibr" rid="bibr5-0092861512457774">5</xref>
         </sup> and the Japanese Pharmaceuticals and Medical Devices Agency.<sup>
            <xref ref-type="bibr" rid="bibr6-0092861512457774">6</xref>
         </sup>
      </p>
      <p>The introduction of the journal’s new Regulatory Commentary category is therefore timely, and the first two such commentaries appear in this issue. The first addresses the need for data standardization if data from multiple sources are to be most usefully employed together to yield the higher-order information and knowledge that they are capable of doing.<sup>
            <xref ref-type="bibr" rid="bibr7-0092861512457774">7</xref>
         </sup> The second discusses how the FDA and Pharmaceutical Users Software Exchange (PhUSE) have joined forces and set up working groups that will help to harness the power of computational science, particularly in the setting of providing innovative ideas that address regulatory informatics challenges.<sup>
            <xref ref-type="bibr" rid="bibr8-0092861512457774">8</xref>
         </sup> Readers are encouraged to join this initiative so that as many stakeholders as possible can contribute.</p>
      <p>We hope that regulators from agencies worldwide will contribute commentaries to this section to share their latest thinking on regulatory science with our wide readership. Please contact me or the journal’s Managing Editor, Ms Judy Connors, if you would like to discuss this opportunity.</p>
      <sig-block>
         <sig>—J. Rick Turner, PhD</sig>
         <sig>
            <italic>Editor-in-Chief</italic>
         </sig>
      </sig-block>
   </body>
   <back>
      <ref-list>
         <title>References</title>
         <ref id="bibr1-0092861512457774">
            <label>1</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Turner</surname>
                     <given-names>JR</given-names>
                  </name>
               </person-group>. <article-title>Editor’s commentary: celebrating the journal’s new name—<italic>Therapeutic Innovation &amp; Regulatory Science</italic>
               </article-title>. <source>Drug Information Journal</source>. <year>2012</year>;<volume>46</volume>(<issue>4</issue>):<fpage>391</fpage>.</citation>
         </ref>
         <ref id="bibr2-0092861512457774">
            <label>2</label>
            <citation citation-type="web" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Hamburg</surname>
                     <given-names>MA</given-names>
                  </name>
               </person-group>. <article-title>Remarks at the National Press Club speaker luncheon, October 6, 2010</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/NewsEvents/Speeches/ucm229195.htm" xlink:type="simple">http://www.fda.gov/NewsEvents/Speeches/ucm229195.htm</ext-link>. <comment>Accessed July 17, 2012</comment>.</citation>
         </ref>
         <ref id="bibr3-0092861512457774">
            <label>3</label>
            <citation citation-type="web" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">US Food and Drug Administration</collab>. <article-title>Advancing regulatory science for public health: a framework for FDA’s regulatory science initiative</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/ucm228131.htm" xlink:type="simple">http://www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/ucm228131.htm</ext-link>. <comment>Published October 2010. Accessed July 17, 2012</comment>.</citation>
         </ref>
         <ref id="bibr4-0092861512457774">
            <label>4</label>
            <citation citation-type="web" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">US Food and Drug Administration</collab>. <article-title>Advancing regulatory science at the FDA: a strategic plan</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/ucm267719.htm" xlink:type="simple">http://www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/ucm267719.htm</ext-link>. <comment>Published August 2011. Accessed July 17, 2012</comment>.</citation>
         </ref>
         <ref id="bibr5-0092861512457774">
            <label>5</label>
            <citation citation-type="web" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">European Medicines Agency website</collab>. <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000479.jsp&amp;mid=WC0b01ac058026369c" xlink:type="simple">http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000479.jsp&amp;mid=WC0b01ac058026369c</ext-link>. <comment>Accessed July 17, 2012</comment>.</citation>
         </ref>
         <ref id="bibr6-0092861512457774">
            <label>6</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Tominaga</surname>
                     <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Asahina</surname>
                     <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Uyama</surname>
                     <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Kondo</surname>
                     <given-names>T</given-names>
                  </name>
               </person-group>. <article-title>Regulatory science as a bridge between science and society</article-title>. <source>Clin Pharmacol Ther</source>. <year>2011</year>;<volume>90</volume>:<fpage>29</fpage>–<lpage>31</lpage>.</citation>
         </ref>
         <ref id="bibr7-0092861512457774">
            <label>7</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Cooper</surname>
                     <given-names>CK</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Buckman-Garner</surname>
                     <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Slack</surname>
                     <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Florian</surname>
                     <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                     <surname>McCune</surname>
                     <given-names>S.</given-names>
                  </name>
               </person-group> 
               <article-title>Developing standardized data: connecting the silos</article-title>. <source>Drug Information Journal</source>. <year>2012</year>;<volume>46</volume>(<issue>5</issue>):<fpage>521</fpage>–<lpage>522</lpage>.</citation>
         </ref>
         <ref id="bibr8-0092861512457774">
            <label>8</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Rosario</surname>
                     <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Kropp</surname>
                     <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Wilson</surname>
                     <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Cooper</surname>
                     <given-names>CK.</given-names>
                  </name>
               </person-group> 
               <article-title>Join FDA/PhUSE Working Groups to help harness the power of computational science</article-title>. <source>Drug Information Journal</source>. <year>2012</year>;<volume>46</volume>(<issue>5</issue>):<fpage>523</fpage>–<lpage>524</lpage>.</citation>
         </ref>
      </ref-list>
   </back>
</article>